FilingsTodayHyundai Pharmaceutical
At a glance
Hyundai Pharmaceutical filed 22 disclosures in the last 12 months, including 1 5% holder, 1 buyback and 1 m&a. The most recent key filing was on Mar 4.
Revenue for 2025 was ₩192B, up 9.1% on 2024. Operating margin was 2.2% against 0.1% a year earlier. Debt was 99% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩102B and operating profit of ₩3.5B.
The 2025 annual report lists 399 employees with an average tenure of 9.4 years and average pay of ₩71.7M, #553 of 1,829 listed companies by average pay. Its 4 directors and auditors were paid ₩133M each on average. It paid ₩30 per common share in cash dividends, against ₩30 a year earlier (+0%). 이한구 and related parties held 24.26% at year end.
From the 2025 annual report
Staff: 399 (313 men, 86 women), of whom 11 on fixed-term contracts. Total pay for the year: ₩28.6B. Directors and auditors: 4, paid ₩534M in total.
Dividends (common shares)
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash dividend per share | ₩30 | ₩30 | ₩35 |
| Payout ratio | 31.2% | -136.4% | 15.2% |
| Yield (as filed) | 0.25% | 0.87% | 0.91% |
| Total cash dividends | ₩784M | ₩784M | ₩923M |
Largest shareholder
이한구 holds 17.88%; with 7 related parties the group holds 24.26% of common shares at year end.
Individuals paid ₩500M or more
| 이한구 회장 | ₩800M |
Auditor: 삼화회계법인 · opinion: Unqualified.
Source: 2025 annual business report (DART). How figures are combined
Financial summary
Key filings
Other filings
Links open the original filing on DART, in Korean.